コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 e appropriateness for all groups affected by rheumatic heart disease.
2 s acute rheumatic fever (ARF) and subsequent rheumatic heart disease.
3 a significant decrease in the prevalence of rheumatic heart disease.
4 ome, and atrial fibrillation associated with rheumatic heart disease.
5 hey had echocardiographic evidence of latent rheumatic heart disease.
6 ed episodes that had already compounded into rheumatic heart disease.
7 diagnosing definite compared with borderline rheumatic heart disease.
8 zing soft-tissue infection, renal damage and rheumatic heart disease.
9 d in 43% of patients, primarily secondary to rheumatic heart disease.
10 d control strategies for rheumatic fever and rheumatic heart disease.
11 adolescents 5 to 17 years of age with latent rheumatic heart disease.
12 including cardiac surgery for congenital and rheumatic heart disease.
13 he best opportunity to address the burden of rheumatic heart disease.
14 sorders, including schistosomiasis, HIV, and rheumatic heart disease.
15 ange of life-threatening diseases, including rheumatic heart disease.
16 nd its peptides appear during progression of rheumatic heart disease.
17 ad prosthetic valve endocarditis, and 5% had rheumatic heart disease.
18 c myosin is important in the pathogenesis of rheumatic heart disease.
19 e postinfection sequelae rheumatic fever and rheumatic heart disease.
20 have been implicated in the pathogenesis of rheumatic heart disease.
21 tissues, and subsequent rheumatic fever and rheumatic heart disease.
22 be an important event in the development of rheumatic heart disease.
23 t myosin are associated with myocarditis and rheumatic heart disease.
24 nts (38%; 15 with bicuspid valves); probable rheumatic heart disease, 8 patients (6%); and miscellane
25 e with the adverse consequences of untreated rheumatic heart disease, a condition that is largely pre
26 e of the composite of definite or borderline rheumatic heart disease according to the World Heart Fed
29 ess whether enhanced prophylaxis support for rheumatic heart disease, administered through community
32 for early detection of subclinical stages of rheumatic heart disease among children in endemic region
33 rval, 29.7 million to 43.1 million) cases of rheumatic heart disease and 10.5 million (95% uncertaint
34 re is no vaccine to prevent diseases such as rheumatic heart disease and invasive streptococcal infec
35 ive autoantibodies which target the valve in rheumatic heart disease and the neuronal cell in Sydenha
36 countries, including the cardiac effects of rheumatic heart disease and the vascular effects of mala
37 327 were initially assessed as having latent rheumatic heart disease, and 926 of the 3327 subsequentl
38 se, nonischemic and Chagas cardiomyopathies, rheumatic heart disease, and congenital heart anomalies,
40 ifferences in the prevalence and severity of rheumatic heart disease, and level of training or expert
41 id aortic valves, mitral valve prolapse, and rheumatic heart disease, and outline the fundamental mol
42 prevalent pretransition forms of HF such as rheumatic heart disease, and underdevelopment of healthc
44 iomyopathy, atrial fibrillation and flutter, rheumatic heart disease, aortic aneurysm, peripheral art
45 n and diagnosis of acute rheumatic fever and rheumatic heart disease are key to preventing progressio
47 Acute rheumatic fever (ARF) and subsequent rheumatic heart disease are rare but serious sequelae of
48 arly detection and the treatment of clinical rheumatic heart disease are required to improve outcomes
49 ds in the prevalence of and mortality due to rheumatic heart disease as part of the 2015 Global Burde
50 on of cardiovascular events in patients with rheumatic heart disease-associated atrial fibrillation h
54 up, the odds ratio of definite or borderline rheumatic heart disease at follow-up vs baseline was 0.2
56 her rates of congestive heart failure (CHF), rheumatic heart disease, atrial fibrillation, clotting d
57 ularly in the management of rheumatic fever, rheumatic heart disease, bacterial endocarditis, syphili
58 health of women with unoperated and operated rheumatic heart disease before, during, and after pregna
59 and years of life lost (YLL) as measures of rheumatic heart disease burden using the GBD Results Too
61 ey had a history of a myocardial infarction, rheumatic heart disease, cardiomyopathy, significant val
65 and all valvular (n=2504) disease deaths and rheumatic heart disease deaths (n=4713) were studied.
66 Global age-standardized mortality due to rheumatic heart disease decreased by 47.8% (95% uncertai
67 re) compared to those with RHD alone suggest rheumatic heart disease defines their clinical outcome m
68 ncer due to hepatitis B virus (9.4 million), rheumatic heart disease due to streptococcal infection (
69 de association study (GWAS), the Genetics of Rheumatic Heart Disease, examined more than 7 million ge
70 atically reviewed data on fatal and nonfatal rheumatic heart disease for the period from 1990 through
71 ent of patients with atrial fibrillation and rheumatic heart disease, for the treatment of patients w
72 ort the 2-year follow-up of individuals with rheumatic heart disease from 14 low- and middle-income c
78 an monoclonal antibodies (mAbs) derived from rheumatic heart disease have provided evidence for cross
80 mary prevention of acute rheumatic fever and rheumatic heart disease in children presenting with phar
83 on for the management of rheumatic fever and rheumatic heart disease in India, and the benefits of pu
86 high-income countries, and a predominance of rheumatic heart disease in low-income and middle-income
90 Evidence suggested that the pathogenesis of rheumatic heart disease involved the activation of surfa
96 phylaxis in children with evidence of latent rheumatic heart disease may be an effective strategy to
97 art disease were older than children without rheumatic heart disease (median age [interquartile range
99 ality, and classified countries according to rheumatic heart disease mortality in 2017 and 1990-2017.
100 22%) had both the highest level of premature rheumatic heart disease mortality in 2017 and the smalle
103 ce, quantified cross-country inequalities in rheumatic heart disease mortality, and classified countr
104 for and diagnosing acute rheumatic fever and rheumatic heart disease needs further investigation.
105 GBD 2017 estimated that 3 604 800 cases of rheumatic heart disease occurred overall in the Americas
106 e current management strategies for valvular rheumatic heart disease on the basis of either strong ev
107 pared with other primary presentations) were rheumatic heart disease or congestive cardiac failure, c
108 the mortality and morbidity associated with rheumatic heart disease or information on their predicto
109 surface antigens may lead to valve damage in rheumatic heart disease or neuropsychiatric behaviors an
110 dividuals with a personal history of chronic rheumatic heart disease (OR = 0.55; 0.33-0.93), particul
111 aphic and environmental determinants of CVD, rheumatic heart disease, out-of-hospital cardiac arrest,
114 t resource allocation on rheumatic fever and rheumatic heart disease prevention and control in India.
115 is is the only intervention known to prevent rheumatic heart disease progression, yet delivery of pro
116 ally associated with intravenous drug abuse, rheumatic heart disease, prosthetic heart valves, pacema
117 increased occurrence of CLL and how chronic rheumatic heart disease protects against CLL, perhaps re
119 , 2017, to March 31, 2020, enrolled at three rheumatic heart disease registry sites in Uganda (in Mba
123 e of acute rheumatic fever in North America, rheumatic heart disease remains an infrequent cause of v
129 diologic diagnosis, has been associated with rheumatic heart disease (RHD) and rheumatic fever (RF).
130 people with acute rheumatic fever (ARF) and rheumatic heart disease (RHD) and the effect of comorbid
132 emporaneous estimate of the global burden of rheumatic heart disease (RHD) from echocardiographic pop
134 enetic variations and biomarkers of risk for rheumatic heart disease (RHD) in continental Africans, a
135 ncreasingly implicated in the development of rheumatic heart disease (RHD) in lower-resource settings
140 s in reported HLA class II associations with rheumatic heart disease (RHD) may have been due to inacc
142 ite possessing such knowledge for >70 years, rheumatic heart disease (RHD) remains the most common ca
144 hildren and adolescents, which may evolve to rheumatic heart disease (RHD) with persistent cardiac va
147 acute rheumatic fever (ARF) and its sequel, rheumatic heart disease (RHD), continue to cause a large
148 c screening can detect asymptomatic cases of rheumatic heart disease (RHD), facilitating access to tr
154 adolescents 5 to 17 years of age with latent rheumatic heart disease, secondary antibiotic prophylaxi
156 e a reduction in global mortality related to rheumatic heart disease since 1900, the death rate has r
159 and left atrial calcification compared with rheumatic heart disease, suggesting a potential shift in
160 integration of community health workers into rheumatic heart disease supports within the public healt
161 one transitions in developed countries, from rheumatic heart disease to a degenerative calcific patho
162 ealth Assembly 2018 approved a resolution on rheumatic heart disease to strengthen programmes in coun
163 predominantly communicable diseases such as rheumatic heart disease, tuberculous pericarditis, or ca
164 g and diagnosis of acute rheumatic fever and rheumatic heart disease using handheld echocardiography
165 The prevalence of borderline or definite rheumatic heart disease was 10.2 (95% CI, 7.5-13.0) per
166 The prevalence of definite or borderline rheumatic heart disease was 10.8 per 1000 children (95%
167 e various repair techniques, perhaps because rheumatic heart disease was less common, and the initial
168 ccuracy (AUC 0.90 [0.85-0.94]) for screening rheumatic heart disease was observed when pooling data o
169 ndardized mortality due to and prevalence of rheumatic heart disease were observed in Oceania, South
171 curacy (AUC 0.94 [0.84-1.00]) for diagnosing rheumatic heart disease when compared with standard echo
172 llation and echocardiographically documented rheumatic heart disease who had any of the following: a